Resource Summary Report

Generated by SPARC SAWG on Aug 9, 2026

Monoclonal Anti-Vinculin antibody produced in mouse

RRID:AB_477617
Type: Antibody

Proper Citation

Sigma-Aldrich Cat# V4505, RRID:AB_477617

Antibody Information

URL: http://antibodyregistry.org/AB_477617

Proper Citation: Sigma-Aldrich Cat# V4505, RRID:AB_477617

Target Antigen: Vinculin antibody produced in mouse

Host Organism: mouse

Clonality: monoclonal

Comments: Vendor recommendations: IgG1 Other; Western Blot; Immunofluorescence; microarray: suitable, immunoblotting: suitable, indirect immunofluorescence: 1:50

Antibody Name: Monoclonal Anti-Vinculin antibody produced in mouse

Description: This monoclonal targets Vinculin antibody produced in mouse

Target Organism: chicken, mouse, chickenbird, bovine, human

Antibody ID: AB_477617

Vendor: Sigma-Aldrich

Catalog Number: V4505

Record Creation Time: 20250819T204843+0000

Record Last Update: 20250819T205401+0000

Ratings and Alerts

No rating or validation information has been found for Monoclonal Anti-Vinculin antibody produced in mouse.

No alerts have been found for Monoclonal Anti-Vinculin antibody produced in mouse.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 58 mentions in open access literature.

Listed below are recent publications. The full list is available at SPARC SAWG .

Kumariya S, et al. (2026) Transcriptional control of PPP2CB by YAP1 and TEAD1 mediates AMPK inhibition and mTORC1 activation in vascular smooth muscle cells. iScience, 29(3), 114996.

Spindler J, et al. (2026) SLX4IP limits replication stress globally and at ALT telomeres. The EMBO journal, 45(12), 4176.

Milano L, et al. (2026) BRCA2-dependent maturation of nascent strands during DNA replication. Molecular cell, 86(8), 1427.

Ghuloum FI, et al. (2026) A Modular Bioinstructive Platform Reveals Mechanistic Insights into Additive-Free, Topography-Driven Osteogenesis. Advanced healthcare materials, 15(18), e04865.

Mao C, et al. (2026) DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer. Cancer research, 86(13), 3309.

Goldman A, et al. (2026) An LRRK2 variant blocks NCOA4 trafficking upon iron overload, leading to ferroptotic death. Journal of cell science, 139(14).

Fu Z, et al. (2026) Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer. Cancer cell.

Lei G, et al. (2026) Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell.

Lei G, et al. (2025) Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance. Cancer cell, 43(6), 1076.

Lavanderos B, et al. (2025) Rhotekin-1 is a novel interacting protein and regulator of TRPC6 activity. The FEBS journal, 292(16), 4353.

Yu H, et al. (2025) Energy status orchestrates YTHDF1 phase separation and tumorigenesis. Cell reports, 44(11), 116466.

Ho-Xuan H, et al. (2025) YTHDF proteins and m6A-RNA clients undergo autophagic turnover during contact inhibition. Cell reports, 44(9), 116188.

Song W, et al. (2025) Targeting the UFL1-PARP1 axis amplifies anti-tumor immunity. Cell reports, 44(10), 116433.

Madej M, et al. (2025) PUS10-induced tRNA fragmentation impacts retrotransposon-driven inflammation. Cell reports, 44(6), 115735.

Cigrang M, et al. (2025) Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity. Nature communications, 16(1), 512.

Ryu JE, et al. (2024) Circadian regulation of endoplasmic reticulum calcium response in cultured mouse astrocytes. eLife, 13.

Mao C, et al. (2024) Unraveling ETC complex I function in ferroptosis reveals a potential ferroptosis-inducing therapeutic strategy for LKB1-deficient cancers. Molecular cell, 84(10), 1964.

Brock K, et al. (2024) A comparative analysis of paxillin and Hic-5 proximity interactomes. Cytoskeleton (Hoboken, N.J.).

Zhang D, et al. (2024) Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy. EBioMedicine, 105, 105212.

Hao M, et al. (2024) In??vivo CRISPR knockout screen identifies p47 as a suppressor of HER2+ breast cancer metastasis by regulating NEMO trafficking and autophagy flux. Cell reports, 43(2), 113780.